403 related articles for article (PubMed ID: 18362666)
21. The inhibitory effect of different concentrations of topical bevacizumab on corneal neovascularization.
Habot-Wilner Z; Barequet IS; Ivanir Y; Moisseiev J; Rosner M
Acta Ophthalmol; 2010 Dec; 88(8):862-7. PubMed ID: 19549103
[TBL] [Abstract][Full Text] [Related]
22. Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium.
Bahar I; Kaiserman I; McAllum P; Rootman D; Slomovic A
Curr Eye Res; 2008 Jan; 33(1):23-8. PubMed ID: 18214740
[TBL] [Abstract][Full Text] [Related]
23. The effect of bevacizumab on corneal neovascularization in rabbits.
Kim WJ; Jeong HO; Chung SK
Korean J Ophthalmol; 2010 Aug; 24(4):230-6. PubMed ID: 20714387
[TBL] [Abstract][Full Text] [Related]
24. Subconjunctival bevacizumab for corneal neovascularization.
Doctor PP; Bhat PV; Foster CS
Cornea; 2008 Oct; 27(9):992-5. PubMed ID: 18812760
[TBL] [Abstract][Full Text] [Related]
25. Subconjunctival injection of bevacizumab in the treatment of corneal neovascularization associated with lipid deposition.
Chu HS; Hu FR; Yang CM; Yeh PT; Chen YM; Hou YC; Chen WL
Cornea; 2011 Jan; 30(1):60-6. PubMed ID: 20847676
[TBL] [Abstract][Full Text] [Related]
26. Comparative study of tacrolimus and bevacizumab on corneal neovascularization in rabbits.
Park JH; Joo CK; Chung SK
Cornea; 2015 Apr; 34(4):449-55. PubMed ID: 25651492
[TBL] [Abstract][Full Text] [Related]
27. Anti-VEGF therapy (bevacizumab) for sulfur mustard-induced corneal neovascularization associated with delayed limbal stem cell deficiency in rabbits.
Kadar T; Amir A; Cohen L; Cohen M; Sahar R; Gutman H; Horwitz V; Dachir S
Curr Eye Res; 2014 May; 39(5):439-50. PubMed ID: 24215293
[TBL] [Abstract][Full Text] [Related]
28. The anti-inflammatory effect of subconjunctival bevacizumab on chemically burned rat corneas.
Oh JY; Kim MK; Shin MS; Lee HJ; Lee JH; Wee WR
Curr Eye Res; 2009 Feb; 34(2):85-91. PubMed ID: 19219678
[TBL] [Abstract][Full Text] [Related]
29. Mechanisms controlling the effects of bevacizumab (avastin) on the inhibition of early but not late formed corneal neovascularization.
Chen WL; Chen YM; Chu HS; Lin CT; Chow LP; Chen CT; Hu FR
PLoS One; 2014; 9(4):e94205. PubMed ID: 24714670
[TBL] [Abstract][Full Text] [Related]
30. Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis.
Hosseini H; Nejabat M; Mehryar M; Yazdchi T; Sedaghat A; Noori F
Clin Exp Ophthalmol; 2007 Nov; 35(8):745-8. PubMed ID: 17997779
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin).
Manzano RP; Peyman GA; Khan P; Carvounis PE; Kivilcim M; Ren M; Lake JC; Chévez-Barrios P
Br J Ophthalmol; 2007 Jun; 91(6):804-7. PubMed ID: 17179168
[TBL] [Abstract][Full Text] [Related]
32. Subconjunctival bevacizumab for corneal neovascularization.
Zaki AA; Farid SF
Acta Ophthalmol; 2010 Dec; 88(8):868-71. PubMed ID: 19519730
[TBL] [Abstract][Full Text] [Related]
33. Subconjunctival and intracorneal bevacizumab injection for corneal neovascularization in lipid keratopathy.
Oh JY; Kim MK; Wee WR
Cornea; 2009 Oct; 28(9):1070-3. PubMed ID: 19724199
[TBL] [Abstract][Full Text] [Related]
34. [Subconjunctival bevacizumab for corneal neovascularization].
Gueudry J; Richez F; Tougeron-Brousseau B; Genevois O; Muraine M
J Fr Ophtalmol; 2010 Nov; 33(9):630-6. PubMed ID: 21035899
[TBL] [Abstract][Full Text] [Related]
35. Combined use of subconjunctival and intracorneal bevacizumab injection for corneal neovascularization.
Yeung SN; Lichtinger A; Kim P; Amiran MD; Slomovic AR
Cornea; 2011 Oct; 30(10):1110-4. PubMed ID: 21673570
[TBL] [Abstract][Full Text] [Related]
36. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis.
Bock F; Onderka J; Dietrich T; Bachmann B; Kruse FE; Paschke M; Zahn G; Cursiefen C
Invest Ophthalmol Vis Sci; 2007 Jun; 48(6):2545-52. PubMed ID: 17525183
[TBL] [Abstract][Full Text] [Related]
37. Compensatory growth factor and cytokine response in tears after subconjunctival bevacizumab injection.
Jeong JH; Chun YS; Kim ES; Kim JC
Cornea; 2011 Oct; 30(10):1071-7. PubMed ID: 21775887
[TBL] [Abstract][Full Text] [Related]
38. Effect of Conbercept on Corneal Neovascularization in a Rabbit Model.
Du L; Sun J; Liu J; Xu N; Liu M; Wu X
Semin Ophthalmol; 2023 Oct; 38(7):670-678. PubMed ID: 37058000
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of Subconjunctival Aflibercept Versus Bevacizumab for Prevention of Corneal Neovascularization in a Rat Model.
Gal-Or O; Livny E; Sella R; Nisgav Y; Weinberger D; Livnat T; Bahar I
Cornea; 2016 Jul; 35(7):991-6. PubMed ID: 27124775
[TBL] [Abstract][Full Text] [Related]
40. The effect of subconjunctival ranibizumab on corneal and anterior segment neovascularization: study on an animal model.
Liarakos VS; Papaconstantinou D; Vergados I; Douvali M; Theodossiadis PG
Eur J Ophthalmol; 2014; 24(3):299-308. PubMed ID: 24242219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]